Drug-target interaction prediction through domain-tuned network-based inference.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 23720490.
- Also identified by DOI 10.1093/bioinformatics/btt307 and PMC identifier 3722516.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
MOTIVATION: The identification of drug-target interaction (DTI) represents a costly and time-consuming step in drug discovery and design. Computational methods capable of predicting reliable DTI play an important role in the field. Recently, recommendation methods relying on network-based inference (NBI) have been proposed. However, such approaches implement naive topology-based inference and do not take into account important features within the drug-target domain. RESULTS: In this article, we present a new NBI method, called domain tuned-hybrid (DT-Hybrid), which extends a well-established recommendation technique by domain-based knowledge including drug and target similarity. DT-Hybrid has been extensively tested using the last version of an experimentally validated DTI database obtained from DrugBank. Comparison with other recently proposed NBI methods clearly shows that DT-Hybrid is capable of predicting more reliable DTIs. AVAILABILITY: DT-Hybrid has been developed in R and it is available, along with all the results on the predictions, through an R package at the following URL: http://sites.google.com/site/ehybridalgo/.
Medical subject headings
- Drug Discovery
- Protein Structure, Tertiary